|
|||||
|
|
Treatment of Acute Myeloblastic Leukaemia with RP 22050 |
|
| Authors: | C Jacquillat M Weil M F Gemon V Izrael G Schaison M Boiron Jean Bernard |
| Abstract: | Fourty-four patients with acute myeloblastic leukaemia were treated with RP 22050, a new, semisynthetic derivative of daunorubicin. Complete remissions were achieved in 20 patients (45%). The median dose given was 23 mg/kg. The toxicity of RP 22050 is mainly haematological. Resistance rather than death in aplasia seemed to be the cause of failure of therapy. |
| Keywords: | |